Q-omics provides the consensus-scored VPS4B profile across patient tissues and cancer cell-line models. VPS4B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, VPS4B is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, VPS4B RNA expression shows 20,171 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where VPS4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS4B survival associations across molecular data types. VPS4B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS4B RNA expression–survival associations across cancer types. High VPS4B expression shows unfavorable associations in PAAD, ACC, MESO and STAD, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for VPS4B RNA expression.
This table summarizes VPS4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS4B shows lower tumor expression in COAD, THCA and KICH and higher tumor expression in LIHC, CHOL and LUSC. The COAD box plot shows higher VPS4B RNA expression in normal versus tumor tissue (log2 FC = −1.175, t-test p < 0.001).
This table shows molecular features associated with VPS4B in patient tissues and cancer cell lines. In patient samples, VPS4B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
